Halo Pharmaceutical has named Allen Rosenston as its new vice president of business development. He comes to Halo from Abbott Laboratories where he held roles in operations, business development, and other business functions.
The president of the Parenteral Drug Association (PDA), Bob Myers, has taken the decision to retire. Myers has a long history of dedicated service to PDA, both as a volunteer and as staff leader. He will be leaving in mid-2009.
Terry Ladd has rejoined US contract research organisation (CRO) Calvert Labs as vice president of business development. Ladd had previously worked at Calvert Labs as executive director, business development and marketing between 1994 and 2003.
Pharma and biotech services group Excelsyn said that Peter Chinigo has been appointed to lead the company’s business development drive in the US.
Kathryn Kimmel has been elected chair of the academy board of trustees for the Association of Clinical Research Professionals (ACRP). The academy oversees ACRP certification functions related to members who are CRAs, clinical research coordinators (CRCs) and nonphysician clinical trial investigators (CTIs). Kimmel works for Clinsys Clinical Research.
Dr Derek Ellison has been appointed chief operating officer at Eden Biodesign, a UK-based provider of contract biologics manufacturing services. The appointment has been made as Eden’s business operations expand into the US.
In other restructuring at the firm: Dr Anita Bate, (Co-Founder of Eden) will take up the role of chief scientific officer, having previously served as science director; Dr Phil Ball moves from the UK to the US to serve as technical director; Dr David Simpson becomes process development manager; Dr Mandy Shipman takes up the role of biopharm development consultant; Gina Wenham takes on responsibility for the analytical development team alongside quality control; and Alison Justice has been promoted to QA director.
India's Dr Reddy's Laboratories has appointed Umang Vohra as chief financial officer, replacing Saumen Chakraborty who takes on the newly-created role of president of corporate and global generics operations.